Outcomes of rare patients with a primary cutaneous CD30(+) lymphoproliferative disorder developing extracutaneous disease

R.C. Melchers, R. Willemze, J.S.P. Vermaat, P.M. Jansen, L.A. Daniels, H. Putter, M.W. Bekkenk, E.R.M. de Haas, B. Horvath, M.M. van Rossum, C.J.G. Sanders, J.C.J.M. Veraart, M.H. Vermeer, K.D. Quint

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)769-773
Number of pages6
JournalBlood
Volume135
Issue number10
DOIs
Publication statusPublished - 5 Mar 2020

Keywords

  • brentuximab vedotin
  • classification
  • diagnosis
  • eortc
  • guidelines
  • iscl
  • large-cell lymphoma
  • papulosis
  • DIAGNOSIS
  • PAPULOSIS
  • EORTC
  • GUIDELINES
  • BRENTUXIMAB VEDOTIN
  • CLASSIFICATION
  • LARGE-CELL LYMPHOMA
  • ISCL

Cite this